Skip to main content
Top
Published in: BMC Medicine 1/2021

Open Access 01-12-2021 | Research article

Development of a model of medication review for use in clinical practice: Bristol medication review model

Authors: D. McCahon, R. E. Denholm, A. L. Huntley, S. Dawson, P. Duncan, R. A. Payne

Published in: BMC Medicine | Issue 1/2021

Login to get access

Abstract

Background

Medication review is a core aspect of medicine optimisation, yet existing models of review vary substantially in structure and content and are not necessarily easy to implement in clinical practice. This study aimed to use evidence from the existing literature to identify key medication review components and use this to inform the design of an improved review model.

Methods

A systematic review was conducted (PROSPERO: CRD42018109788) to identify randomised control trials of stand-alone medication review in adults (18+ years). The review updated that by Huiskes et al. (BMC Fam Pract. 18:5, 2017), using the same search strategy implemented in MEDLINE and Embase. Studies were assessed using the Cochrane risk of bias tool. Key review components were identified, alongside relevant clinical and health service outcomes. A working group (patients, doctors and pharmacists) developed the model through an iterative consensus process (appraisal of documents plus group discussions), working from the systematic review findings, brief evidence summaries for core review components and examples of previous models, to agree on the main purpose of the review model, overarching model structure, review components and supporting material.

Results

We identified 28 unique studies, with moderate bias overall. Consistent medication review components included reconciliation (26 studies), safety assessment (22), suboptimal treatment (19), patient knowledge/preferences (18), adherence (14), over-the-counter therapy (13) and drug monitoring (10). There was limited evidence from studies for improvement in key clinical outcomes. The review structure was underpinned by patient values and preferences, with parallel information gathering and evaluation stages, feeding into the final decision-making and implementation. Most key components identified in the literature were included. The final model was considered to benefit from a patient-centred, holistic approach, which captured both patient-orientated and medication-focused problems, and aligned with traditional consultation methods thus facilitating implementation in practice.

Conclusions

The Bristol Medication Review Model provides a framework for standardised delivery of structured reviews. The model has the potential for use by all healthcare professionals with relevant clinical experience and is designed to offer flexibility of implementation not limited to a particular healthcare setting.
Appendix
Available only for authorised users
Literature
5.
go back to reference Duerden M, Avery AJ, Payne RA. Polypharmacy and medicines optimisation: making it safe and sound. King’s Fund. 2013. Duerden M, Avery AJ, Payne RA. Polypharmacy and medicines optimisation: making it safe and sound. King’s Fund. 2013.
7.
go back to reference NICE. Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. Clinical Guideline NG5. 2015 NICE. Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. Clinical Guideline NG5. 2015
9.
go back to reference World Health Organization. Medication safety in polypharmacy: technical report. 2019;WHO/UHC/SDS/2019.11 World Health Organization. Medication safety in polypharmacy: technical report. 2019;WHO/UHC/SDS/2019.11
14.
go back to reference Ali S, Salahudeen MS, Bereznicki LRE, Curtain CM. Pharmacist-led interventions to reduce adverse drug events in older people living in residential aged care facilities: a systematic review. Br J Clin Pharmacol. 2021. https://doi.org/10.1111/bcp.14824. Ali S, Salahudeen MS, Bereznicki LRE, Curtain CM. Pharmacist-led interventions to reduce adverse drug events in older people living in residential aged care facilities: a systematic review. Br J Clin Pharmacol. 2021. https://​doi.​org/​10.​1111/​bcp.​14824.
17.
go back to reference Rose O, Cheong VL, Dhaliwall S, et al. Standards in medication review: an international perspective. Can Pharm J (Ott). 2020;153:215–23.CrossRef Rose O, Cheong VL, Dhaliwall S, et al. Standards in medication review: an international perspective. Can Pharm J (Ott). 2020;153:215–23.CrossRef
20.
go back to reference Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011
21.
go back to reference Beuscart JB, Knol W, Cullinan S, et al. International core outcome set for clinical trials of medication review in multi-morbid older patients with polypharmacy. BMC Med. 2018;16:21.CrossRef Beuscart JB, Knol W, Cullinan S, et al. International core outcome set for clinical trials of medication review in multi-morbid older patients with polypharmacy. BMC Med. 2018;16:21.CrossRef
22.
go back to reference Fischer F, Lange K, Klose K, et al. Barriers and strategies in guideline implementation - a scoping review. Healthcare (Basel). 2016;4:36.CrossRef Fischer F, Lange K, Klose K, et al. Barriers and strategies in guideline implementation - a scoping review. Healthcare (Basel). 2016;4:36.CrossRef
23.
go back to reference Scottish Government Polypharmacy Model of Care Group. Polypharmacy guidance, realistic prescribing 3rd edition, 2018. Edinburgh: Scottish Government. Scottish Government Polypharmacy Model of Care Group. Polypharmacy guidance, realistic prescribing 3rd edition, 2018. Edinburgh: Scottish Government.
Metadata
Title
Development of a model of medication review for use in clinical practice: Bristol medication review model
Authors
D. McCahon
R. E. Denholm
A. L. Huntley
S. Dawson
P. Duncan
R. A. Payne
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2021
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-021-02136-9

Other articles of this Issue 1/2021

BMC Medicine 1/2021 Go to the issue